Journal of neuroimmunology · 2025
Pilot analysis of Chitinase-3-like protein 1 and soluble Syndecan-1 CSF levels as potential biomarkers in relapsing-remitting multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uluc Firdevs, Ceylan Dursun, Turkoglu Sule Aydin
Аннотация
BACKGROUND: Chitinase-3-like protein 1 (CHI3L1), secreted by immune cells, plays a key role in modulating immune responses. Syndecan-1 (SDC-1), a cell surface heparan sulfate proteoglycan, is involved in the regulation of inflammation. This study aimed to evaluate whether CHI3L1 and soluble SDC-1 (sSDC-1) act as potential diagnostic targets in patients with relapsing-remitting multiple sclerosis (RRMS).
METHODS: sSDC-1 and CHI3L1 levels were quantified using enzyme-linked immunosorbent assay (ELISA) in cerebrospinal fluid (CSF) samples collected from a cohort of 39 newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) and 32 disease controls diagnosed with idiopathic intracranial hypertension (IIH).
RESULTS: No significant difference was observed in CSF sSDC-1 levels between the RRMS and IIH groups. However, CSF CHI3L1 levels were significantly lower in patients with RRMS compared to those with IIH.
CONCLUSION: The present findings do not provide clear evidence supporting a diagnostic role for CSF levels of sSDC-1 or CHI3L1 in MS.
METHODS: sSDC-1 and CHI3L1 levels were quantified using enzyme-linked immunosorbent assay (ELISA) in cerebrospinal fluid (CSF) samples collected from a cohort of 39 newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) and 32 disease controls diagnosed with idiopathic intracranial hypertension (IIH).
RESULTS: No significant difference was observed in CSF sSDC-1 levels between the RRMS and IIH groups. However, CSF CHI3L1 levels were significantly lower in patients with RRMS compared to those with IIH.
CONCLUSION: The present findings do not provide clear evidence supporting a diagnostic role for CSF levels of sSDC-1 or CHI3L1 in MS.